Collegium Pharmaceutical Inc (NASDAQ:COLL) – Research analysts at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a report issued on Sunday. Jefferies Group analyst D. Steinberg now expects that the specialty pharmaceutical company will post earnings of ($2.58) per share for the year, up from their previous estimate of ($2.61). Jefferies Group currently has a “Buy” rating and a $32.00 price target on the stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s Q4 2017 earnings at ($0.64) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at $0.30 EPS, FY2021 earnings at $1.62 EPS and FY2022 earnings at $2.64 EPS.

COLL has been the subject of a number of other reports. Piper Jaffray Companies set a $19.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, November 29th. BidaskClub upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, December 29th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Needham & Company LLC increased their price objective on Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $27.17.

Collegium Pharmaceutical (NASDAQ:COLL) opened at $25.50 on Wednesday. The stock has a market capitalization of $806.54 and a PE ratio of -8.59. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $26.77.

In other Collegium Pharmaceutical news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $17.34, for a total value of $17,340,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $500,200.00. Following the completion of the transaction, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,055,558 shares of company stock valued at $18,570,177. Corporate insiders own 25.76% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Nationwide Fund Advisors lifted its position in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Collegium Pharmaceutical by 12.7% in the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 3,285 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in shares of Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Collegium Pharmaceutical by 10.5% in the fourth quarter. California State Teachers Retirement System now owns 39,499 shares of the specialty pharmaceutical company’s stock valued at $729,000 after buying an additional 3,752 shares during the last quarter. Finally, Teton Advisors Inc. lifted its position in shares of Collegium Pharmaceutical by 18.5% in the fourth quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after buying an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 82.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/jefferies-group-comments-on-collegium-pharmaceutical-incs-fy2017-earnings-coll/1866831.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.